Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H7N9 Vaccine with AS03 or MF59 Adjuvants in Healthy Adults
NCT01942265Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2013
- Primary completion
- Jan 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MF59-adjuvanted H7N9 vaccine in Influenza A H7N9 Infection (H7N9), sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2013; status: completed.
02
Drugs
MF59-adjuvanted H7N9 vaccine
03
Conditions
Influenza A H7N9 Infection (H7N9)
Beyond the preview
Go deeper on NCT01942265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01942265.